Xconomy | Seattle - Business + Technology in the Exponential Economy

Biotech, Financing, Hedge Funds

ZymoGenetics Receives $100 Million Commitment From Deerfield

Luke Timmerman 6/30/08

ZymoGenetics (NASDAQ: ZGEN) said today it has received a $100 million funding commitment from Deerfield Management, a biotech hedge fund. The Seattle-based company can draw the money in $25 million increments anytime over the next 18 months, and plans to use it to build its business with Recothrom, a drug for surgical bleeding. Deerfield will get a 2 percent royalty on Recothrom sales for every $25 million request by ZymoGenetics, the company said.


Add Your Thoughts



You will have 10 minutes to edit your post after you press publish.

Comments may be edited for clarity and length, rejected, or deleted. By clicking "Publish," you are agreeing to these Terms and Conditions.

    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.

© 2007-2008 Xconomy. All rights reserved. Site designed by Matthew Bouchard, produced by Andrew Koyfman, and powered by WordPress.